Clinical trials
Immunodeficiency clinical trials
Below are recruiting immunodeficiency clinical trials, each written for real people, not researchers. We’re tracking 130 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04232085RecruitingPhase 2
Stem cell transplant to rebuild immunity in genetic immune disorders
This Phase 2 trial tests a stem cell (bone marrow) transplant approach to restore bone marrow function and immune function in people with certain inherited immune problems. If you have one of these conditions and a suitable donor, the study may offer a path to rebuild blood and immune systems.
Baltimore, MarylandAges 4 months–50 years - NCT04430257Recruiting
PrEP for people at higher risk of HIV
This study checks whether taking HIV prevention medicine called PrEP can help protect people who are not living with HIV but have recent risk of HIV exposure. You may qualify if you have ongoing risk and are not already taking PrEP.
Cambridge, MassachusettsAges 18 years+ - NCT04528355Recruiting
Study of hospital data after stem cell transplant for non-cancer illness
This study collects medical information from people with certain non-cancer conditions who receive a stem cell transplant. It may help doctors better understand transplant outcomes and care, since the study focuses on data collection rather than adding new treatment.
Pittsburgh, PennsylvaniaAges 2 months–60 years - NCT04691622RecruitingPhase 1
Treat chronic norovirus using donor immune cells
This Phase 1 study tests whether giving immune cells made from a donor can help children and adults with long-lasting (chronic) norovirus infection. It’s aimed at people whose immune system is weakened after a stem cell transplant, solid organ transplant, or due to primary immune problems.
Washington D.C., District of ColumbiaAges 3 months–80 years - NCT04760574Recruiting
HIV status and low testosterone in men
This study looks at whether low testosterone (often called male hypogonadism) is linked to having HIV. It compares HIV-positive men with HIV-negative men to better understand what contributes to hormone problems and how common they are.
TaipeiAges 20 years+ - NCT04864886Recruiting
Study how immune-related conditions affect metabolism
This study collects blood and other samples to see how the immune system changes “metabolism” (how your body uses energy) in people with immune-related conditions. Your samples may also be stored for future research and could help researchers better understand immune health.
Bethesda, MarylandAges 18–75 - NCT07266831RecruitingPhase 2/Phase 3
Study of islatravir and ulonivirine for new HIV patients
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Los Angeles, CaliforniaAges 18 years+ - NCT04943861Recruiting
Study on HIV and food insecurity support
This study is looking at food insecurity in adults living with HIV. It may help improve understanding of the barriers to healthy living and guide better support for people affected by HIV.
Winston-Salem, North CarolinaAges 18 years+ - NCT04958122RecruitingPhase 3
Antibiotic treatment trial for early syphilis
This Phase 3 study tests whether cefixime can treat primary, secondary, or early latent syphilis. It may help by offering another effective antibiotic option, including for some people who also have HIV (if well controlled).
Los Angeles, CaliforniaAges 18 years+ - NCT04990908Recruiting
Screening children in ICU for immune problems after severe infection
This study checks children in pediatric intensive care for possible “immune system problems” after a severe infection. The goal is to find primary immunodeficiencies early, which may change follow-up and treatment for the child’s immune health.
MontpellierAges 3 months–16 years - NCT05159466Recruiting
Transplant from HIV-positive donors to HIV-positive recipients
This trial studies whether it’s safe and effective for HIV-positive people to receive organ transplants from HIV-positive donors. It focuses on matching HIV treatment before and after transplant and checking for major complications.
Metairie, LouisianaAges 18 years+ - NCT05183854RecruitingPhase 2
Vaccine study for CLL patients to prevent pneumococcal infections
This trial tests a series of two pneumococcal vaccines (PCV20 and PPSV23) in people with CLL-related immune weakness. It aims to see how well the vaccines work and how safe they are for preventing serious lung infections.
Salt Lake City, UtahAges 18 years+ - NCT05193552RecruitingPhase 4
Spirometry study for people with CVID on IG therapy
This trial looks at how breathing tests (spirometry) can help guide treatment decisions for people with CVID and airway disease who are already on immune globulin (IG) therapy. It may help your care team better monitor lung function using a specific breathing-test pattern.
Birmingham, AlabamaAges 21 years+ - NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT05452564RecruitingPhase 2
Baricitinib to help reduce HIV in the brain
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
Atlanta, GeorgiaAges 18–65 - NCT05495906RecruitingPhase 4
Lower-dose HPV vaccine study for women with HIV
This trial tests whether giving a lower dose of the HPV vaccine can still be effective and safe for women living with HIV. It may be helpful if you need HPV protection and the study’s dose schedule could reduce vaccine burden.
Surrey, British ColumbiaAges 18–45 - NCT05537935RecruitingPhase 4
Low-dose naltrexone for nerve pain in people with HIV
This trial studies whether a low dose of naltrexone can reduce long-lasting nerve-related pain in adults living with HIV. It may help if your pain has been ongoing and you have stable HIV control.
Atlanta, GeorgiaAges 18–75 - NCT05587894RecruitingPhase 2
Testing optimized COVID antiviral treatment in immunocompromised adults
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
Bordeaux, BordeauxAges 16 years+ - NCT05642858Recruiting
Learn heart health tips for people living with HIV
This study tests a text-message education program to help people living with HIV manage cardiovascular (heart and blood vessel) health. It may be helpful if you are 40 or older and can use a smartphone to receive messages.
San Francisco, CaliforniaAges 40 years+ - NCT05651113Recruiting
Your experience during screening for SCID
This study looks at what it feels like for people to go through screening for SCID (a rare immune condition). It may help improve the screening process and support for patients and families.
LondonAges 18 years+ - NCT05786547RecruitingPhase 3
Varenicline plus support to help quit tobacco in HIV care
This Phase 3 trial tests a quit-smoking program using varenicline (a medicine) plus additional support, for people with HIV who currently use tobacco. It may help you stop smoking or using tobacco and stay quit with safer, guided care.
Aurora, ColoradoAges 18 years+ - NCT05858034Recruiting
Study of aging and frailty in people with HIV over 50
This study looks at what makes some people with HIV become “pre-frail” or frail as they get older. It uses questionnaires and other checks to understand challenges to healthy aging and may help improve future support and care.
Winston-Salem, North CarolinaAges 50 years+ - NCT05968573Recruiting
Health messages intervention for people at risk of HIV or HCV
This study tests whether persuasive, health-message coaching can help people reduce risk for HIV or hepatitis C (HCV). You may be eligible if you’re not infected with HIV or HCV and haven’t been tested for either in the last year.
New York, New YorkAges 18 years+ - NCT06088277Recruiting
Texting to reduce HIV risk for dental patients
This study tests if daily text messages can help people lower their risk of getting HIV. You'll receive texts for a few months and complete surveys to see if the messages help.
Boston, MassachusettsAges 18 years+
Hear when a new Immunodeficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunodeficiency?
- Yes. Clin2 currently lists 130 recruiting immunodeficiency studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunodeficiency trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunodeficiency trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.